Camp4 Therapeutics CEO Josh Mandel-Brehm acquires 6,551 common shares for $10,809.15
CAMP•CEO buys common shares
- Camp4 Therapeutics CEO Josh Mandel-Brehm bought 6,551 common shares at $1.65 each.
- His direct holding rose to 284,968 shares.
CAMP•CAMP•
